Andrew G. Gianoukakis

4.7k total citations · 1 hit paper
63 papers, 3.3k citations indexed

About

Andrew G. Gianoukakis is a scholar working on Endocrinology, Diabetes and Metabolism, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andrew G. Gianoukakis has authored 63 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Pathology and Forensic Medicine and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andrew G. Gianoukakis's work include Thyroid Cancer Diagnosis and Treatment (32 papers), Thyroid Disorders and Treatments (15 papers) and Ophthalmology and Eye Disorders (9 papers). Andrew G. Gianoukakis is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (32 papers), Thyroid Disorders and Treatments (15 papers) and Ophthalmology and Eye Disorders (9 papers). Andrew G. Gianoukakis collaborates with scholars based in United States, France and United Kingdom. Andrew G. Gianoukakis's co-authors include Terry J. Smith, Raymond S. Douglas, Corina E. Dutcus, Lori J. Wirth, Marcia S. Brose, Makoto Tahara, Steven I. Sherman, Manisha H. Shah, Bruce Robinson and Martin Schlumberger and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andrew G. Gianoukakis

60 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

2015 1.4k citations Martin Schlumberger, Makoto Tahara et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Andrew G. Gianoukakis

Since Specialization

Citations

This map shows the geographic impact of Andrew G. Gianoukakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew G. Gianoukakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew G. Gianoukakis more than expected).

Fields of papers citing papers by Andrew G. Gianoukakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew G. Gianoukakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew G. Gianoukakis. The network helps show where Andrew G. Gianoukakis may publish in the future.

Co-authorship network of co-authors of Andrew G. Gianoukakis

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew G. Gianoukakis. A scholar is included among the top collaborators of Andrew G. Gianoukakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew G. Gianoukakis. Andrew G. Gianoukakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement 2025 ·The Lancet Diabetes & Endocrinology ·Sophie Leboulleux, Laura Boucai, Naifa L. Busaidy, Cosimo Durante, James A. Fagin, (unknown), Andrew G. Gianoukakis, Bryan R. Haugen, Hyunseok Kang, Bhavana Konda, Theodore W. Laetsch, Laura D. Locati, Mabel Ryder, Christine Spitzweg, Francis P. Worden, Lori J. Wirth, Alan L. Ho	1
2	Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers 2024 ·Clinical Cancer Research ·Jena D. French, Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu, Eric J. Sherman, (unknown), Nathan R. Foster, Yuri E. Nikiforov, (unknown), Paul J. Norman, Lori J. Wirth	10
3	Abstract B043: Preliminary results from a phase I/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies 2023 ·Molecular Cancer Therapeutics ·Elena Garralda, (unknown), Pilar Garrido, Andrew G. Gianoukakis, Matthew Taylor, Sarina A. Piha‐Paul, Matthew Krebs, Antoîne Italiano, Liz Clark, (unknown), (unknown), Vivek Subbiah	3
4	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) 2022 ·Journal of Clinical Oncology ·Alan L. Ho, Marek Dedecjus, Lori J. Wirth, R. Michael Tuttle, William B. Inabnet, Jan Tennvall, Fernanda Vaisman, Lars Bastholt, Andrew G. Gianoukakis, Patrice Rodien, Ralf Paschke, Rossella Elisei, David Viola, Karen So, Danielle Carroll, (unknown), (unknown), James A. Fagin, (unknown)	37
5	An Assessment of Diversity, Inclusion, and Health Equity Training in Endocrinology Fellowship Programs in the United States 2022 ·Endocrine Practice ·Rana Malek, Amal Shibli‐Rahhal, Ricardo Correa, Emily D. Szmuilowicz, (unknown), (unknown), (unknown), Andrew G. Gianoukakis, (unknown), David C. Lieb, J. Sonya Haw, Sarah E. Mayson	2
6	426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg 2020 ·Annals of Oncology ·Marcia S. Brose, (unknown), Bhavana Konda, Christelle de la Fouchardière, Brett Hughes, Andrew G. Gianoukakis, (unknown), (unknown), Monika K. Krzyzanowska, (unknown), Corina E. Dutcus, Ran Xie, Matthew H. Taylor	11
7	1917P Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial 2020 ·Annals of Oncology ·Bryan R. Haugen, Jena D. French, Francis P. Worden, Bhavana Konda, Eric J. Sherman, Ramona Dadu, Andrew G. Gianoukakis, (unknown), Nathan R. Foster, Daniel W. Bowles, Lori J. Wirth	8
8	The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence 2020 ·Thyroid ·(unknown), Steven I. Sherman, Youngju Pak, Danielle R. Litofsky, Andrew G. Gianoukakis, (unknown), Kenneth B. Ain, S. Thomas Bigos, James D. Brierley, David S. Cooper, Henry G. Fein, Bryan R. Haugen, Jacqueline Jonklaas, Paul W. Ladenson, Harry R. Maxon, Donald S.A. McLeod, Douglas S. Ross, Monica C. Skarulis, David L. Steward	14
9	Endothelial Cell Growth Promoting Activity in Graves’ Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy 2019 ·PubMed ·Mark B. Zimering, John Shin, (unknown), (unknown), Andrew G. Gianoukakis	2
10	Prolonged duration of response in lenvatinib responders with thyroid cancer 2018 ·Endocrine Related Cancer ·Andrew G. Gianoukakis, Corina E. Dutcus, Nicolas Batty, Matthew Guo, Mahadi Baig	68
11	Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer 2018 ·European Journal of Cancer ·Makoto Tahara, Marcia S. Brose, Lori J. Wirth, Takuya Suzuki, (unknown), (unknown), Corina E. Dutcus, Andrew G. Gianoukakis	80
12	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer breakdown → 2015 ·New England Journal of Medicine ·Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman	1408
13	Thyroglobulin antibody status and differentiated thyroid cancer 2014 ·Current Opinion in Oncology ·Andrew G. Gianoukakis	12
14	CD34+ Fibrocytes May Over-arch the Orbit and Thyroid in Patients with Graves’ Disease and Ophthalmopathy 2011 ·Investigative Ophthalmology & Visual Science ·Dolly Ann Padovani-Claudio, Roshini Fernando, Stephen Atkins, Gerard M. Doherty, Paul G. Gauger, Barbra S. Miller, Andrew G. Gianoukakis, Raymond S. Douglas, Terry J. Smith	1
15	Management of Severe Thyrotoxicosis When the Gastrointestinal Tract Is Compromised 2011 ·Thyroid ·Eman Alfadhli, Andrew G. Gianoukakis	16
16	B Cells from Patients with Graves’ Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis 2008 ·The Journal of Immunology ·Raymond S. Douglas, Vibhavari Naik, Catherine J. Hwang, Nikoo F. Afifiyan, Andrew G. Gianoukakis, Daniel Sand, Shweta Kamat, Terry J. Smith	112
17	Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves’ Disease 2008 ·The Journal of Immunology ·Shanli Tsui, Vibhavari Naik, Neil Hoa, Catherine J. Hwang, Nikoo F. Afifiyan, Amiya Sinha Hikim, Andrew G. Gianoukakis, Raymond S. Douglas, Terry J. Smith	282
18	Characterization of the anaemia associated with Graves’ disease 2008 ·Clinical Endocrinology ·Andrew G. Gianoukakis, Mary Jacena Leigh, Patrick Richards, Peter D. Christenson, (unknown), Paul Fu, Yutaka Niihara, Terry J. Smith	34
19	Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves’ Disease May Carry Functional Consequences for Disease Pathogenesis 2007 ·The Journal of Immunology ·Raymond S. Douglas, Andrew G. Gianoukakis, Shweta Kamat, Terry J. Smith	124
20	Monoclonal Pathogenic Antibodies to the Thyroid-Stimulating Hormone Receptor in Graves’ Disease with Potent Thyroid-Stimulating Activity but Differential Blocking Activity Activate Multiple Signaling Pathways 2006 ·The Journal of Immunology ·Jacqueline A. Gilbert, Andrew G. Gianoukakis, Albert Salehi, (unknown), (unknown), Mahmood Khan, Alan M. McGregor, Terry J. Smith, J. Paul Banga	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact